Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

RMD US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

RMD US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Resmed Inc(RMD US)

Ask AI
ProfileEntity StructureAll DocumentsFinancialsChartingEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Resmed Inc(RMD US)

Ask AI
ProfileEntity StructureAll DocumentsFinancialsChartingEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
All Documents

Financials & Metrics

FinancialsChartingEmployees
All Documents

Financials & Metrics

FinancialsChartingEmployees

Resmed Inc — Company Profile

ResMed Inc. is a leading global medical technology company specializing in the development, manufacturing, and distribution of medical devices and digital health solutions for the healthcare sector. Its operations are divided into two primary segments: Sleep and Respiratory Care, and Software as a Service (SaaS). The Sleep and Respiratory Care division offers a comprehensive range of products addressing various respiratory disorders. This includes advanced technologies for medical and consumer applications, ventilation devices, diagnostic tools, mask systems for both hospital and home use, headgear, other accessories, and dental devices. This segment also incorporates cloud-based informatics software designed to improve patient outcomes. Specific digital health offerings include AirView, a cloud-based system enabling remote monitoring and adjustment of patient device settings; myAir, a personalized therapy management application for sleep apnea patients providing support, education, and troubleshooting; and U-Sleep, a compliance monitoring solution that helps home medical equipment (HME) providers optimize their sleep programs. Additionally, ResMed offers connectivity modules, Propeller solutions, and the Propeller portal. Through its Software as a Service segment, ResMed delivers a suite of out-of-hospital software solutions. These comprise Brightree, a business management software and service platform for providers of HME, pharmacy, home infusion, orthotics, and prosthetics; MatrixCare, which offers comprehensive care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, alongside related accountable care organizations; and HEALTHCAREfirst, providing electronic health record (EHR) software, billing and coding services, and analytics for home health and hospice agencies. ResMed markets its extensive product line to sleep clinics, home healthcare dealers, and hospitals. The company utilizes a network of distributors and a direct sales force to reach customers in approximately 140 countries globally. Founded in 1989, ResMed Inc. maintains its headquarters in San Diego, California.

Sector
Industrials
Industry
Commercial Services & Supplies
Exchange
UN
CEO
Michael J. Farrell
Headquarters
San Diego, CA, US
IPO Date
Jun 2, 1995
Employees
11,370
Website
www.resmed.com

Key Metrics

Price
$218.89
Market Cap
$31.75B
Revenue (TTM)
$1.43B

Resmed Inc — Company Profile

ResMed Inc. is a leading global medical technology company specializing in the development, manufacturing, and distribution of medical devices and digital health solutions for the healthcare sector. Its operations are divided into two primary segments: Sleep and Respiratory Care, and Software as a Service (SaaS). The Sleep and Respiratory Care division offers a comprehensive range of products addressing various respiratory disorders. This includes advanced technologies for medical and consumer applications, ventilation devices, diagnostic tools, mask systems for both hospital and home use, headgear, other accessories, and dental devices. This segment also incorporates cloud-based informatics software designed to improve patient outcomes. Specific digital health offerings include AirView, a cloud-based system enabling remote monitoring and adjustment of patient device settings; myAir, a personalized therapy management application for sleep apnea patients providing support, education, and troubleshooting; and U-Sleep, a compliance monitoring solution that helps home medical equipment (HME) providers optimize their sleep programs. Additionally, ResMed offers connectivity modules, Propeller solutions, and the Propeller portal. Through its Software as a Service segment, ResMed delivers a suite of out-of-hospital software solutions. These comprise Brightree, a business management software and service platform for providers of HME, pharmacy, home infusion, orthotics, and prosthetics; MatrixCare, which offers comprehensive care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, alongside related accountable care organizations; and HEALTHCAREfirst, providing electronic health record (EHR) software, billing and coding services, and analytics for home health and hospice agencies. ResMed markets its extensive product line to sleep clinics, home healthcare dealers, and hospitals. The company utilizes a network of distributors and a direct sales force to reach customers in approximately 140 countries globally. Founded in 1989, ResMed Inc. maintains its headquarters in San Diego, California.

Sector
Industrials
Industry
Commercial Services & Supplies
Exchange
UN
CEO
Michael J. Farrell
Headquarters
San Diego, CA, US
IPO Date
Jun 2, 1995
Employees
11,370
Website
www.resmed.com

Key Metrics

Price
$218.89
Market Cap
$31.75B
Revenue (TTM)
$1.43B
Net Income (TTM)
$398.73M
EPS (TTM)
2.72
P/E (TTM)
20.90
P/B (TTM)
4.89
Dividend Yield
118.54%
ROE (TTM)
6.14%
ROA (TTM)
4.54%
Operating Margin
34.92%
Beta
0.31

Dividends

Last Dividend
$0.60
Last Yield
1.19%

Summary

ResMed Inc. is a leading global medical technology company specializing in the development, manufacturing, and distribution of medical devices and digital health solutions for the healthcare sector. Its operations are divided into two primary segments: Sleep and Respiratory Care, and Software as a Service (SaaS). The Sleep and Respiratory Care division offers a comprehensive range of products addressing various respiratory disorders. This includes advanced technologies for medical and consumer applications, ventilation devices, diagnostic tools, mask systems for both hospital and home use, headgear, other accessories, and dental devices. This segment also incorporates cloud-based informatics software designed to improve patient outcomes. Specific digital health offerings include AirView, a cloud-based system enabling remote monitoring and adjustment of patient device settings; myAir, a personalized therapy management application for sleep apnea patients providing support, education, and troubleshooting; and U-Sleep, a compliance monitoring solution that helps home medical equipment (HME) providers optimize their sleep programs. Additionally, ResMed offers connectivity modules, Propeller solutions, and the Propeller portal. Through its Software as a Service segment, ResMed delivers a suite of out-of-hospital software solutions. These comprise Brightree, a business management software and service platform for providers of HME, pharmacy, home infusion, orthotics, and prosthetics; MatrixCare, which offers comprehensive care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, alongside related accountable care organizations; and HEALTHCAREfirst, providing electronic health record (EHR) software, billing and coding services, and analytics for home health and hospice agencies. ResMed markets its extensive product line to sleep clinics, home healthcare dealers, and hospitals. The company utilizes a network of distributors and a direct sales force to reach customers in approximately 140 countries globally. Founded in 1989, ResMed Inc. maintains its headquarters in San Diego, California.

Website
www.resmed.com
Location
San Diego, CA, US
Phone858 836 5000
Employees11,370
CEOMichael J. Farrell
Sector
Industrials
Industry
Commercial Services & Supplies
IPO DateJun 2, 1995

Latest Documents

SEC Filings(2.6K)

Expand
  • Form 4FARRELL PETER C03:57PM
  • Form 4De Witte Jan03:50PM
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers19 Nov
  • Form 4De Witte Jan18 Nov
  • Form 144De Witte Jan17 Nov
  • Form 4Farrell Michael J.13 Nov
  • Form 4Bloomer Aaron13 Nov
  • Form 4FARRELL PETER C13 Nov
  • Form 4De Witte Jan13 Nov
  • Form 4Gill Harjit13 Nov
  • Form 4Rider Michael J13 Nov
  • Form 4Farrell Michael J.12 Nov
  • Form 144Farrell Michael J.9 Nov
  • 10-QQ1ended 30 Sept 202629 Oct
  • 8-KFor investorsFor media+1 [email protected]@resmed.com29 Oct
  • Form 4Rider Michael J26 Oct
  • Form 144Rider Michael J23 Oct
  • Form 4Farrell Michael J.8 Oct
  • Form 144Farrell Michael J.7 Oct
  • ARSAnnual report to security holders1 Oct

Mentions in Filings

  • we receive marketing approval for Oxnimbi, we will consider our primary competition to be PAP, which is the typical first-line therapy for patients diagnosed with moderate to severe OSA. Two leading PAP manufacturers are <strong>ResMed</strong> Corp. and Philips N.V. (through its subsidiary Respironics Inc.). We will additionally face competition from surgically implanted devices, such as Inspire® by Inspire, a hypoglossal nerve stimulation system that is target …
    Apnimed, Inc.Resmed Inc·10-Q - Quarterly report Q3·Q3 26·16 Nov
  • we receive marketing approval for Oxnimbi, we will consider our primary competition to be PAP, which is the typical first-line therapy for patients diagnosed with moderate to severe OSA. Two leading PAP manufacturers are <strong>ResMed</strong> Corp. and Philips N.V. (through its subsidiary Respironics Inc.). We will additionally face competition from surgically implanted devices, such as Inspire® by Inspire, a hypoglossal nerve stimulation system that is target …
    Apnimed, Inc.Resmed Inc·10-Q/A - Quarterly report (amendment) Q2·Q2 26·13 Nov
  • … ty Graciela I. Monteagudo Former President and Chief Executive Officer Lala U.S., Inc. David B. Pendarvis Corporate Governance Committee Chair Former Chief Administrative Officer, Global General Counsel and Secretary <strong>ResMed Inc.</strong> Ken A. Plunk Former Chief Financial Officer and SVP Information Technology J&J Snack Foods Corp. Anne G. Saunders Former President, U.S. nakedwines.com STOCK INFORMATION The common stock of the Company is traded on …
    WD 40 COResmed Inc·ARS - Annual report to security holders·FY26·30 Oct
  • … HOLDINGS INC | 3,656 | 282.48 | 1,032,746.88 | | | | MCKESSON CORP | 5,257 | 937.14 | 4,926,544.98 | | | | MEDTRONIC PLC | 54,095 | 97.58 | 5,278,590.10 | | | | QUEST DIAGNOSTICS INC | 4,604 | 202.44 | 932,033.76 | | | | <strong>RESMED</strong> INC | 6,287 | 256.29 | 1,611,295.23 | | | | SOLVENTUM CORP | 6,302 | 73.61 | 463,890.22 | | | | STERIS PLC | 4,267 | 251.18 | 1,071,785.06 | | | | STRYKER CORP | 14,518 | 372.66 | 5,410,277.88 | | | | UNITEDHEALTH GROUP I …
    りそなアセットマネジメント株式会社Resmed Inc·Prospectus - Securities registration statement·20 Nov·19 Nov
  • … | 222.710 | 3,754,445.180 | | | | BOOKING HOLDINGS | 65,320 | 193.290 | 12,625,702,800 | | | | ROSS STORES INC | 27,156 | 230.690 | 6,264,617.640 | | | | Packaging Corp of America | 7,464 | 237.250 | 1,770,834.000 | | | | <strong>RESMED</strong> | 12,228 | 228.350 | 2,792,263.800 | | | | QUEST DIAGNOSTICS INC | 9,331 | 237.140 | 2,212,753.340 | | | | MODERNA | 29,769 | 145.550 | 4,332,877.950 | | | | RALPH LAUREN CLASS A | 3,259 | 351.200 | 1,144,560.800 | | | | …
    大和アセットマネジメント株式会社Resmed Inc·Prospectus - Securities registration statement·19 Nov·18 Nov
  • … | 222.710 | 3,754,445.180 | | | | BOOKING HOLDINGS | 65,320 | 193.290 | 12,625,702,800 | | | | ROSS STORES INC | 27,156 | 230.690 | 6,264,617.640 | | | | Packaging Corp of America | 7,464 | 237.250 | 1,770,834.000 | | | | <strong>RESMED</strong> | 12,228 | 228.350 | 2,792,263.800 | | | | QUEST DIAGNOSTICS INC | 9,331 | 237.140 | 2,212,753.340 | | | | MODERNA | 29,769 | 145.550 | 4,332,877.950 | | | | RALPH LAUREN CLASS A | 3,259 | 351.200 | 1,144,560.800 | | | | …
    大和アセットマネジメント株式会社Resmed Inc·Annual Report - Annual Securities Report (2025.09.09-2026.09.07)·19 Nov·18 Nov

Key Stats

Trading

Px/Chg 1D$218.89 / -1.02%
Avg Volume1.28M
Beta0.31
Mkt Cap31.75B
FD Mkt Cap34.90B

Float

Shrs Out/Float145.06M / 144.16M
Short Float0.10%
Days to Cover8.49
Stock Repurchased$175.01M

Current Valuation

EV30.93B
EV/EBITDA14.15
EV/Sales5.59
P/B4.89
P/S5.73
FCF Yield1.64%
ROE6.14%
ROA4.54%
Current Ratio3.01

Dividend

Cash$0.60
Yield118.54%
Yield (TTM)118.54%

Estimates

P/E20.90
Est P/E0.00
Est EPS2.80
Est PEG0.00

Valuation

Metric5Yr AvgOct '22Oct '23Oct '24Oct '25Oct '26
PRICE-BASED RATIOS
Price / Earnings55.5243.5322.6834.4297.3179.63
Price / Sales14.289.484.827.5027.4122.18
Price / Book Value6.6710.104.937.236.194.89
Price / Free Cash Flow74.27173.9036.4027.3272.7161.00
ENTERPRISE VALUE METRICS
Enterprise Value31,918.534,573.521,712.735,780.936,591.430,934.0
Enterprise Value / Sales14.249.665.147.6427.1521.61
Enterprise Value / EBITDA38.0929.3815.9823.3368.7453.00
Enterprise Value / EBIT44.2335.1818.6827.3079.8860.11

Financials

Full Financials
Millions USD5Yr CAGR (%)Jun '21Jun '22Jun '23Jun '24Jun '25
INCOME STATEMENT
Revenue12.6%3,196.83,578.14,223.04,685.35,146.3
Gross Income13.5%1,839.12,024.32,355.72,655.33,055.0
EBITDA14.7%1,103.91,176.61,358.81,533.51,913.4
EBIT16.4%912.4982.81,162.31,310.51,677.6
Net Income31.1%474.5779.4897.61,021.01,400.7
EPS (Diluted)30.9%3.245.306.096.929.51
BALANCE SHEET
Cash & ST Inv42.3%295.3273.7227.9238.41,209.5
Total Assets14.7%4,728.15,095.96,751.76,872.48,174.4
Total Liabilities4.6%1,842.41,735.12,621.82,008.42,206.5
Total Shareholder Equity19.9%2,885.73,360.84,129.94,864.05,967.9
CASH FLOW
Net Operating Cash Flow24.2%736.7351.1693.31,401.31,751.6
Cap Ex-6.3%-116.8-156.0-134.0-114.9-89.9
Free Cash Flow28%619.9195.1559.31,286.41,661.7

Enterprise Value Bridge

Millions USD20 Nov '26
Price (As of 20 Nov '26)236.94
Basic Shares145.06
Market Cap34,369.7
Diluted Shares147.04
Fully Diluted Shares Outstanding147.04
Fully Diluted Market Cap34,838.9
+Consolidated Debt843.2
−In-the-Money Convertible Debt—
+Capital Leases179.1
+Operating Leases—
−Cash & Equivalents-1,660.5
−Short-term Investments-5.5
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value33,552.3

Related companies

Apple Inc.

AAPL US

Kla Corp

KLAC US

Medtronic Public Limited Company

MDT US

Stryker Corp

SYK US

3M Company

MMM US

Northrop Grumman Corp /DE/

NOC US

Coherent Corp.

COHR US

Boston Scientific Corp

BSX US

Lenovo Group Ltd

LNVGY US

Garmin Ltd

GRMN US

HOYA Corporation

HOCPY US

Becton Dickinson & Co

0R19 LN

Net Income (TTM)
$398.73M
EPS (TTM)
2.72
P/E (TTM)
20.90
P/B (TTM)
4.89
Dividend Yield
118.54%
ROE (TTM)
6.14%
ROA (TTM)
4.54%
Operating Margin
34.92%
Beta
0.31

Dividends

Last Dividend
$0.60
Last Yield
1.19%

Summary

ResMed Inc. is a leading global medical technology company specializing in the development, manufacturing, and distribution of medical devices and digital health solutions for the healthcare sector. Its operations are divided into two primary segments: Sleep and Respiratory Care, and Software as a Service (SaaS). The Sleep and Respiratory Care division offers a comprehensive range of products addressing various respiratory disorders. This includes advanced technologies for medical and consumer applications, ventilation devices, diagnostic tools, mask systems for both hospital and home use, headgear, other accessories, and dental devices. This segment also incorporates cloud-based informatics software designed to improve patient outcomes. Specific digital health offerings include AirView, a cloud-based system enabling remote monitoring and adjustment of patient device settings; myAir, a personalized therapy management application for sleep apnea patients providing support, education, and troubleshooting; and U-Sleep, a compliance monitoring solution that helps home medical equipment (HME) providers optimize their sleep programs. Additionally, ResMed offers connectivity modules, Propeller solutions, and the Propeller portal. Through its Software as a Service segment, ResMed delivers a suite of out-of-hospital software solutions. These comprise Brightree, a business management software and service platform for providers of HME, pharmacy, home infusion, orthotics, and prosthetics; MatrixCare, which offers comprehensive care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, alongside related accountable care organizations; and HEALTHCAREfirst, providing electronic health record (EHR) software, billing and coding services, and analytics for home health and hospice agencies. ResMed markets its extensive product line to sleep clinics, home healthcare dealers, and hospitals. The company utilizes a network of distributors and a direct sales force to reach customers in approximately 140 countries globally. Founded in 1989, ResMed Inc. maintains its headquarters in San Diego, California.

Website
www.resmed.com
Location
San Diego, CA, US
Phone858 836 5000
Employees11,370
CEOMichael J. Farrell
Sector
Industrials
Industry
Commercial Services & Supplies
IPO DateJun 2, 1995

Latest Documents

SEC Filings(2.6K)

Expand
  • Form 4FARRELL PETER C03:57PM
  • Form 4De Witte Jan03:50PM
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers19 Nov
  • Form 4De Witte Jan18 Nov
  • Form 144De Witte Jan17 Nov
  • Form 4Farrell Michael J.13 Nov
  • Form 4Bloomer Aaron13 Nov
  • Form 4FARRELL PETER C13 Nov
  • Form 4De Witte Jan13 Nov
  • Form 4Gill Harjit13 Nov
  • Form 4Rider Michael J13 Nov
  • Form 4Farrell Michael J.12 Nov
  • Form 144Farrell Michael J.9 Nov
  • 10-QQ1ended 30 Sept 202629 Oct
  • 8-KFor investorsFor media+1 [email protected]@resmed.com29 Oct
  • Form 4Rider Michael J26 Oct
  • Form 144Rider Michael J23 Oct
  • Form 4Farrell Michael J.8 Oct
  • Form 144Farrell Michael J.7 Oct
  • ARSAnnual report to security holders1 Oct

Mentions in Filings

  • we receive marketing approval for Oxnimbi, we will consider our primary competition to be PAP, which is the typical first-line therapy for patients diagnosed with moderate to severe OSA. Two leading PAP manufacturers are <strong>ResMed</strong> Corp. and Philips N.V. (through its subsidiary Respironics Inc.). We will additionally face competition from surgically implanted devices, such as Inspire® by Inspire, a hypoglossal nerve stimulation system that is target …
    Apnimed, Inc.Resmed Inc·10-Q - Quarterly report Q3·Q3 26·16 Nov
  • we receive marketing approval for Oxnimbi, we will consider our primary competition to be PAP, which is the typical first-line therapy for patients diagnosed with moderate to severe OSA. Two leading PAP manufacturers are <strong>ResMed</strong> Corp. and Philips N.V. (through its subsidiary Respironics Inc.). We will additionally face competition from surgically implanted devices, such as Inspire® by Inspire, a hypoglossal nerve stimulation system that is target …
    Apnimed, Inc.Resmed Inc·10-Q/A - Quarterly report (amendment) Q2·Q2 26·13 Nov
  • … ty Graciela I. Monteagudo Former President and Chief Executive Officer Lala U.S., Inc. David B. Pendarvis Corporate Governance Committee Chair Former Chief Administrative Officer, Global General Counsel and Secretary <strong>ResMed Inc.</strong> Ken A. Plunk Former Chief Financial Officer and SVP Information Technology J&J Snack Foods Corp. Anne G. Saunders Former President, U.S. nakedwines.com STOCK INFORMATION The common stock of the Company is traded on …
    WD 40 COResmed Inc·ARS - Annual report to security holders·FY26·30 Oct
  • … HOLDINGS INC | 3,656 | 282.48 | 1,032,746.88 | | | | MCKESSON CORP | 5,257 | 937.14 | 4,926,544.98 | | | | MEDTRONIC PLC | 54,095 | 97.58 | 5,278,590.10 | | | | QUEST DIAGNOSTICS INC | 4,604 | 202.44 | 932,033.76 | | | | <strong>RESMED</strong> INC | 6,287 | 256.29 | 1,611,295.23 | | | | SOLVENTUM CORP | 6,302 | 73.61 | 463,890.22 | | | | STERIS PLC | 4,267 | 251.18 | 1,071,785.06 | | | | STRYKER CORP | 14,518 | 372.66 | 5,410,277.88 | | | | UNITEDHEALTH GROUP I …
    りそなアセットマネジメント株式会社Resmed Inc·Prospectus - Securities registration statement·20 Nov·19 Nov
  • … | 222.710 | 3,754,445.180 | | | | BOOKING HOLDINGS | 65,320 | 193.290 | 12,625,702,800 | | | | ROSS STORES INC | 27,156 | 230.690 | 6,264,617.640 | | | | Packaging Corp of America | 7,464 | 237.250 | 1,770,834.000 | | | | <strong>RESMED</strong> | 12,228 | 228.350 | 2,792,263.800 | | | | QUEST DIAGNOSTICS INC | 9,331 | 237.140 | 2,212,753.340 | | | | MODERNA | 29,769 | 145.550 | 4,332,877.950 | | | | RALPH LAUREN CLASS A | 3,259 | 351.200 | 1,144,560.800 | | | | …
    大和アセットマネジメント株式会社Resmed Inc·Prospectus - Securities registration statement·19 Nov·18 Nov
  • … | 222.710 | 3,754,445.180 | | | | BOOKING HOLDINGS | 65,320 | 193.290 | 12,625,702,800 | | | | ROSS STORES INC | 27,156 | 230.690 | 6,264,617.640 | | | | Packaging Corp of America | 7,464 | 237.250 | 1,770,834.000 | | | | <strong>RESMED</strong> | 12,228 | 228.350 | 2,792,263.800 | | | | QUEST DIAGNOSTICS INC | 9,331 | 237.140 | 2,212,753.340 | | | | MODERNA | 29,769 | 145.550 | 4,332,877.950 | | | | RALPH LAUREN CLASS A | 3,259 | 351.200 | 1,144,560.800 | | | | …
    大和アセットマネジメント株式会社Resmed Inc·Annual Report - Annual Securities Report (2025.09.09-2026.09.07)·19 Nov·18 Nov

Key Stats

Trading

Px/Chg 1D$218.89 / -1.02%
Avg Volume1.28M
Beta0.31
Mkt Cap31.75B
FD Mkt Cap34.90B

Float

Shrs Out/Float145.06M / 144.16M
Short Float0.10%
Days to Cover8.49
Stock Repurchased$175.01M

Current Valuation

EV30.93B
EV/EBITDA14.15
EV/Sales5.59
P/B4.89
P/S5.73
FCF Yield1.64%
ROE6.14%
ROA4.54%
Current Ratio3.01

Dividend

Cash$0.60
Yield118.54%
Yield (TTM)118.54%

Estimates

P/E20.90
Est P/E0.00
Est EPS2.80
Est PEG0.00

Valuation

Metric5Yr AvgOct '22Oct '23Oct '24Oct '25Oct '26
PRICE-BASED RATIOS
Price / Earnings55.5243.5322.6834.4297.3179.63
Price / Sales14.289.484.827.5027.4122.18
Price / Book Value6.6710.104.937.236.194.89
Price / Free Cash Flow74.27173.9036.4027.3272.7161.00
ENTERPRISE VALUE METRICS
Enterprise Value31,918.534,573.521,712.735,780.936,591.430,934.0
Enterprise Value / Sales14.249.665.147.6427.1521.61
Enterprise Value / EBITDA38.0929.3815.9823.3368.7453.00
Enterprise Value / EBIT44.2335.1818.6827.3079.8860.11

Financials

Full Financials
Millions USD5Yr CAGR (%)Jun '21Jun '22Jun '23Jun '24Jun '25
INCOME STATEMENT
Revenue12.6%3,196.83,578.14,223.04,685.35,146.3
Gross Income13.5%1,839.12,024.32,355.72,655.33,055.0
EBITDA14.7%1,103.91,176.61,358.81,533.51,913.4
EBIT16.4%912.4982.81,162.31,310.51,677.6
Net Income31.1%474.5779.4897.61,021.01,400.7
EPS (Diluted)30.9%3.245.306.096.929.51
BALANCE SHEET
Cash & ST Inv42.3%295.3273.7227.9238.41,209.5
Total Assets14.7%4,728.15,095.96,751.76,872.48,174.4
Total Liabilities4.6%1,842.41,735.12,621.82,008.42,206.5
Total Shareholder Equity19.9%2,885.73,360.84,129.94,864.05,967.9
CASH FLOW
Net Operating Cash Flow24.2%736.7351.1693.31,401.31,751.6
Cap Ex-6.3%-116.8-156.0-134.0-114.9-89.9
Free Cash Flow28%619.9195.1559.31,286.41,661.7

Enterprise Value Bridge

Millions USD20 Nov '26
Price (As of 20 Nov '26)236.94
Basic Shares145.06
Market Cap34,369.7
Diluted Shares147.04
Fully Diluted Shares Outstanding147.04
Fully Diluted Market Cap34,838.9
+Consolidated Debt843.2
−In-the-Money Convertible Debt—
+Capital Leases179.1
+Operating Leases—
−Cash & Equivalents-1,660.5
−Short-term Investments-5.5
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value33,552.3

Related companies

Apple Inc.

AAPL US

Kla Corp

KLAC US

Medtronic Public Limited Company

MDT US

Stryker Corp

SYK US

3M Company

MMM US

Northrop Grumman Corp /DE/

NOC US

Coherent Corp.

COHR US

Boston Scientific Corp

BSX US

Lenovo Group Ltd

LNVGY US

Garmin Ltd

GRMN US

HOYA Corporation

HOCPY US

Becton Dickinson & Co

0R19 LN